1. Rivaroxaban: Drug information. Lexicomp. (Accessed january 2023, at https://medilib.ir/uptodate/show/9498) [
Article]
2. Tadros R, Shakib S. Warfarin--indications, risks and drug interactions. Aust Fam Physician 2010; 39(7): 476-9. [
PubMed]
3. Kuruvilla M, Gurk-Turner C. A review of warfarin dosing and monitoring. Proc (Bayl Univ Med Cent) 2001; 14(3): 305-6. [
DOI]
4. Barón-Esquivias G, Marín F, Sanmartín Fernandez M. Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice. Expert Rev Cardiovasc Ther 2017; 15(5): 403-13. [
DOI]
5. Chen ST, Hellkamp AS, Becker RC, et al. Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. Eur Heart J Qual Care Clin Outcomes 2019; 5(2): 145-52. [
DOI]
6. Tabatabaie SA, Asharin MR, Assadi M, et al. Comparsion of influence of enoxaparin with unfractioned heparin on acute myocardial infarction with ST-segment elevation. Iran South Med J 2009; 12(3): 198-205. (Persian) [
Article]
7. Liu PH, Liu ZH, Niu MH, et al. A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk. Front Cardiovasc Med 2022; 9: 803233. [
DOI]
8. Perales IJ, San Agustin K, DeAngelo J, et al. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight. Ann Pharmacother 2020; 54(4): 344-50. [
DOI]
9. Weir MR, Ashton V, Moore KT, et al. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease. Am Heart J 2020; 223: 3-11. [
DOI]
10. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883-91. [
DOI]
11. Brown JD, Goodin AJ, Lip GYH, et al. Risk stratification for bleeding complications in patients with venous thromboembolism: application of the HAS‐BLED bleeding score during the first 6 months of anticoagulant treatment. J Am Heart Assoc 2018; 7(6): e007901. [
DOI]
12. Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57(2): 173-80. [
DOI]
13. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients. J Thromb Haemost 2005; 3(4): 692-4. [
DOI]
14. Metzgier-Gumiela A, Skonieczny G, Konieczyńska M, et al. Minor bleeding affects the level of knowledge in patients with atrial fibrillation on oral anticoagulant therapy. Int J Clin Pract 2020; 74(6): e13483. [
DOI]
15. Alberts MJ, He J, Kharat A, et al. Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy. Am J Cardiovasc Drugs 2022; 22(4): 425-36. [
DOI]
16. Coleman CI, Turpie AGG, Bunz TJ, et al. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2- VASc score of 1. Eur Heart J Cardiovasc Pharmacother 2019; 5(2): 64-9. [
DOI]
17. Vinogradova Y, Coupland C, Hill T, et al. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ 2018; 362: k2505. [
DOI]
18. Hong KS, Kwon SU, Lee SH, et al. Rivaroxaban vs Warfarin Sodium in the UltraEarly Period After Atrial Fibrillation-Related Mild Ischemic Stroke: A Randomized Clinical Trial. JAMA Neurol 2017; 74(10): 1206-15. [
DOI]
19. Gorst-Rasmussen A, Lip GY, Bjerregaard Larsen T. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepidemiol Drug Saf 2016; 25(11): 1236-44. [
DOI]
20. Norby FL, Bengtson LGS, Lutsey PL, et al. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord 2017; 17(1): 238. [
DOI]
21. Coleman CI, Thompson S, Ashton V, et al. Rivaroxaban Versus Warfarin in African American Patients with Nonvalvular Atrial Fibrillation. J Natl Med Assoc 2020; 112(4): 395-401. [
DOI]
22. Russo-Alvarez G, Martinez KA, Valente M, et al. Thromboembolic and Major Bleeding Events With Rivaroxaban Versus Warfarin Use in a Real-World Setting. Ann Pharmacother 2018; 52(1): 19-25. [
DOI]
23. Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, et al. Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. Thrombosis 2013; 2013: 640723. [
DOI]
24. Bai Y, Deng H, Shantsila A, et al. Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis. Stroke 2017; 48(4): 970-6. [
DOI]
25. Peterson ED, Ashton V, Chen YW, et al. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. Am Heart J 2019; 212: 113-9. [
DOI]
26. Yao X, Abraham NS, Alexander GC, et al. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc 2016; 5(2): e003074. [
DOI]
27. Gordan H, Beyranvand MR, Sheibani M, et al. Cost Effectiveness of Rivaroxaban versus Warfarin to Prevent Stroke in Iranian AF Patients. Sch Med Stud J 2020; 2(3): 18-24. [
DOI]
28. Jaberi N, Kavosi Z, Hooshmandi E, et al. The study of cost-effectiveness of rivaroxaban versus warfarin in patients with atrial fibrillation who developed ischemic stroke. Stroke Res Treat 2021; 2021: 5534873. [
DOI]
29. Khorvash F, Farajpour-Khanaposhtani MJ, Hemasian H, et al. Evaluation of rivaroxaban versus warfarin for the treatment of cerebral vein thrombosis: A case-control blinded study. Curr J Neurol 2021; 20(3): 125-30. [
DOI]